Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Open accessAbstract
Monoclonal antibodies targeted against the immune checkpoint molecules CTLA-4 and PD-1 have recently obtained approval for the treatment of metastatic melanoma and advanced/refractory non small-cell lung cancers. Therefore, their use will not be limited anymore to selected hospitals involved in clinical trials. Indeed, they will be routinely prescribed in many cancer centers across the world. Besides their efficacy profile, these immune targeted agents also generate immune-related adverse events (irAEs). This new family of dysimmune toxicities remains largely unknown to the broad oncology community. Although severe irAEs remain rare (∼10% of cases under monotherapy), they can become life-threatening if not anticipated and managed appropriately. Over the last 5 years, Gustave Roussy has accumulated a significant experience in the prescription of immune checkpoint blockade (ICB) antibodies and the management of their toxicities. Together with the collaboration of Gustave Roussy's network of organ specialists with expertise in irAEs, we propose here some practical guidelines for the oncologist to help in the clinical care of patients under ICB immunotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Corticosteroids are the usual first-line treatment for both reactive eosinophilic disorders and irAEs.
“Corticosteroids are the usual first-line treatment for both reactive eosinophilic disorders and irAEs.2,7,23”
From Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database (2020) · cites this paper as [2]
Table 4 (p. 571) recommends corticosteroids for grade 2–4 irAEs, with other immunosuppressive drugs considered if symptoms persist; it does not recommend corticosteroids for grade 1 irAEs. The paper does not address first-line treatment of reactive eosinophilic disorders, so it supports only the irAE part of the claim. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works
Self-citationWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 7× · see citing works
“Because chronic infections are known to induce T-cell exhaustion through the expression of immune checkpoints such as PD1 [67], ICB’s administration could be responsible for an inflammatory reaction against such pathogen by reinvigorating the antipathogen immune response.”
BackgroundInfluentialPD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works
Self-citationWolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214 · see citing works
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967 · see citing works
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · see citing works
Self-citationManagement of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · cited 1× · see citing works
“ICBs generate atypical types of tumor responses [15] and have a specific toxicity profile which is challenging the historical oncologists’ practices [16].”
BackgroundWolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · see citing works
Sangro, B., Gómez-Martín, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu‐Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 981 · see citing works
Immune Reconstitution Inflammatory Syndrome
Shelburne, S. A., Hamill, R. J., Rodriguez‐Barradas, M. C., Greenberg, S. B., Atmar, R. L., Musher, D. M., Gathe, J., Visnegarwala, F., & Trautner, B. W. (2002) · Medicine · doi:10.1097/00005792-200205000-00005 · Cited by 654 · see citing works
O'Day, S., Maio, M., Chiarion-Sileni, V., Gajewski, T., Pehamberger, H., Bondarenko, I., Queirolo, P., Lundgren, L., Mikhailov, S., Roman, L., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq013 · Cited by 506 · see citing works
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439 · see citing works
Laubli, H. P., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 320 · see citing works
Chang, K. C., Svabek, C., Guillamet, C. V., Sato, B., Rasche, D. P., Wilson, S., Robbins, P. B., Ulbrandt, N. D., Suzich, J., Green, J. M., et al. (2014) · Critical Care · doi:10.1186/cc13176 · Cited by 307 · see citing works
Anti-CTLA4 Antibody–Induced Lupus Nephritis
Fadel, F., Karoui, K. E., & Knebelmann, B. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0904283 · Cited by 300 · see citing works
Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
Liao, B., Shroff, S., Kamiya-Matsuoka, C., & Tummala, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou001 · Cited by 288 · see citing works
Giacomo, A. M. D., Danielli, R., Guidoboni, M., Calabrò, L., Carlucci, D., Miracco, C., Volterrani, L., Mazzei, M. A., BIAGIOLI, M., Altomonte, M., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0642-y · Cited by 287 · see citing works
Albarel, F., Gaudy‐Marqueste, C., Castinetti, F., Carré, T., Morange, I., Conte‐Devolx, B., Grob, J., & Brue, T. C. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0845 · Cited by 286 · see citing works
Emens, L. A., Braiteh, F. S., Cassier, P. A., Delord, J., Eder, J. P., Fassò, M., Xiao, Y., Wang, Y., Molinero, L. L., Chen, D. S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-2859 · Cited by 211 · see citing works
El-Khoueiry, A. B., Melero, I., Crocenzi, T. S., Welling, T. H., Yau, T. C., Yeo, W., Chopra, A., Grosso, J. F., Lang, L., Anderson, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba101 · Cited by 195 · see citing works
Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
Berthod, G., Lazor, R., Letovanec, I., Romano, E., Noirez, L., Mazza‐Stalder, J., Speiser, D. E., Peters, S., & Michielin, O. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.3298 · Cited by 182 · see citing works
Kidney injuries related to ipilimumab
Izzedine, H., Gueutin, V., Gharbi, C., Mateus, C., Robert, C., Routier, É., Thomas, M., Baumelou, A., & Rouvier, P. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0092-7 · Cited by 170 · see citing works
Self-citationDrugs and autoimmunity – A contemporary review and mechanistic approach
Chang, C. C.-C., & Gershwin, M. E. (2009) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.11.012 · Cited by 165 · see citing works
Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes
Gaudy‐Marqueste, C., Clévy, C., Monestier, S., Dubois, N., Préau, Y., Mallet, S., Richard, M. A., Grob, J., Valéro, R., & Béliard, S. (2015) · Diabetes Care · doi:10.2337/dc15-1331 · Cited by 159 · see citing works
Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma
Robinson, M. R., Chan, C. C., Yang, J. C.-H., Rubin, B. I., Gracia, G. J., Sen, H. N., Csaky, K. G., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00008 · Cited by 159 · see citing works
Varga, A., Piha-Paul, S. A., Ott, P. A., Mehnert, J. M., Berton-Rigaud, D., Johnson, E. A., Cheng, J. D., Yuan, S., Rubin, E. H., & Matei, D. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5510 · Cited by 158 · see citing works
Moskowitz, C. H., Ribrag, V., Michot, J., Martinelli, G., Zinzani, P. L., Gutierrez, M. E., Maeyer, G. D., Jacob, A. G., Giallella, K. M., Anderson, J. W., et al. (2014) · Blood · doi:10.1182/blood.v124.21.290.290 · Cited by 153 · see citing works
Self-citationPathologic Changes in Ipilimumab-Related Hepatitis in Patients with Metastatic Melanoma
Kleiner, D. E., & Berman, D. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-012-2140-5 · Cited by 148 · see citing works
Minkis, K., Garden, B. C., Wu, S., Pulitzer, M. P., & Lacouture, M. E. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2012.12.963 · Cited by 146 · see citing works
Geisler, B. P., Raad, R. A., Esaian, D., Sharon, E., & Schwartz, D. R. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0048-2 · Cited by 144 · see citing works
Neurological immune-related adverse events of ipilimumab
Bot, I., Blank, C. U., Boogerd, W. J., & Brandsma, D. (2013) · Practical Neurology · doi:10.1136/practneurol-2012-000447 · Cited by 131 · see citing works
Kong, Y.-C. M., & Flynn, J. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00206 · Cited by 124 · see citing works
Chan, M. M. K., Kefford, R. F., Carlino, M. S., Clements, A., & Manolios, N. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000060 · Cited by 119 · see citing works
Opportunistic infections in patients treated with immunotherapy for cancer
Kyi, C., Hellmann, M. D., Wolchok, J. D., Chapman, P. B., & Postow, M. A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-19 · Cited by 119 · see citing works
Muro, K., Bang, Y., Shankaran, V., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Berger, R., Gonzalez, E. J., Ray, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.3_suppl.3 · Cited by 118 · see citing works
Plimack, E. R., Joaquim Bellmunt, B., Gupta, S., Berger, R., Montgomery, B., Heath, K., Juco, J. W., Emancipator, K., Pathiraja, K., Lunceford, J. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.4502 · Cited by 115 · see citing works
Disis, M. L., Patel, M. R., Pant, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5509 · Cited by 111 · see citing works
Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Barjaktarević, I., Qadir, N., Suri, A., Santamauro, J. T., & Stover, D. E. (2013) · CHEST Journal · doi:10.1378/chest.12-1467 · Cited by 110 · see citing works
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Hunter, G. R. W., Voll, C., & Robinson, C. A. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100007939 · Cited by 106 · see citing works
Weber, J. S., Antonia, S. J., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Liu, H. Y., Waxman, I. M., & Robert, C. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9018 · Cited by 103 · see citing works
Self-citationLoochtan, A. I., Nickolich, M. S., & Hobson‐Webb, L. D. (2015) · Muscle & Nerve · doi:10.1002/mus.24648 · Cited by 101 · see citing works
Seiwert, T. Y., Haddad, R. I., Gupta, S., Mehra, R., Tahara, M., Berger, R., Lee, S., Burtness, B. A., Le, D. T., Heath, K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba6008 · Cited by 101 · see citing works
Gaudy‐Marqueste, C., Monestier, S., Franques, J., Cantais, E., Richard, M. A., & Grob, J. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31827807dd · Cited by 94 · see citing works
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93 · see citing works
Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
Crosson, J. N., Laird, P. W., Debiec, M. R., Bergstrom, C. S., Lawson, D. H., & Yeh, S. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000066 · Cited by 91 · see citing works
Manusow, J. S., Khoja, L., Pesin, N., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0041-1 · Cited by 90 · see citing works
Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
Akhtari, M., Waller, E. K., Jaye, D. L., Lawson, D. H., Ibrahim, R. A., Papadopoulos, N., & Arellano, M. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819aa40b · Cited by 89 · see citing works
Ipilimumab in patients with melanoma and autoimmune disease
Kyi, C., Carvajal, R. D., Wolchok, J. D., & Postow, M. A. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0035-z · Cited by 88 · see citing works
Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment
de Velasco, G., Bermas, B., & Choueiri, T. K. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39406 · Cited by 84 · see citing works
Diagnosis and classification of drug-induced autoimmunity (DIA)
Xiao, X., & Chang, C. C.-C. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.01.005 · Cited by 82 · see citing works
Ipilimumab‐induced toxicities and the gastroenterologist
Cheng, R., Cooper, A. J., Kench, J. G., Watson, G., Bye, W. A., McNeil, C. M., & Shackel, N. A. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12888 · Cited by 81 · see citing works
Wong, R., Lee, J. K., & Huang, J. J. (2012) · Retinal Cases & Brief Reports · doi:10.1097/icb.0b013e31824f7130 · Cited by 80 · see citing works
Segal, N. H., Ou, S. I., Balmanoukian, A. S., Fury, M. G., Massarelli, E., Brahmer, J. R., Weiss, J., Schöffski, P., Antonia, S. J., Massard, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.3011 · Cited by 80 · see citing works
Abdel-Rahman, O. M., Elhalawani, H. M., & Fouad, M. (2015) · Future Oncology · doi:10.2217/fon.15.118 · Cited by 77 · see citing works
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Gordon, I. O., Wade, T., Chin, K. M., Dickstein, J. I., & Gajewski, T. F. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0627-x · Cited by 77 · see citing works
Nallapaneni, N. N., Mourya, R., Bhatt, V. R., Malhotra, S., Ganti, A. K., & Tendulkar, K. K. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0105 · Cited by 74 · see citing works
Ipilimumab Granulomatous Interstitial Nephritis
Thajudeen, B., Madhrira, M. M., Bracamonte, E. R., et al. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182a32ddc · Cited by 72 · see citing works
Ravi, S., Spencer, K. R., Ruisi, M., Ibrahim, N., Luke, J. J., Thompson, J. A., Shirai, K., Lawson, D. H., Bartell, H., Kudchadkar, R. R., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0033-1 · Cited by 64 · see citing works
Association Between Ipilimumab and Celiac Disease
Gentile, N. M., D’Souza, A., Fujii, L. L., Wu, T., & Murray, J. A. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.01.015 · Cited by 61 · see citing works
Bostwick, A. D., Salama, A. K. S., & Hanks, B. A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0064-2 · Cited by 59 · see citing works
Ipilimumab-induced immune-related renal failure--a case report.
Forde, P. M., Rock, K., Wilson, G. F., et al. (2012) · PubMed · Cited by 59 · see citing works
Pedersen, M., Andersen, R. S., Nørgaard, P. H., Jacobsen, S., Thielsen, P., Straten, P. T., & Svane, I. M. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1607-y · Cited by 58 · see citing works
Serious haematological toxicity during and after ipilimumab treatment: a case series
Simeone, E., Grimaldi, A. M., Esposito, A., Curvietto, M., Palla, M., Paone, M., Mozzillo, N., & Ascierto, P. A. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-240 · Cited by 56 · see citing works
Peripheral Neuropathy Associated With Ipilimumab
Thaipisuttikul, I., Chapman, P. B., & Avila, E. K. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000070 · Cited by 54 · see citing works
Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma
Ahmad, S. S., Lewis, M., Corrie, P. G., et al. (2011) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155211411001 · Cited by 52 · see citing works
Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
Bernardo, S. G., Москаленко, М., Pan, M. M., Shah, S. D., Sidhu, H. K., Sicular, S., Harcharik, S., Chang, R. R., Friedlander, P. A., & Saenger, Y. M. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e32835c7e68 · Cited by 51 · see citing works
Voskens, C., Cavallaro, A., Erdmann, M., Dippel, O., Kaempgen, E., Schuler, G., Schuler‐Thurner, B., & Heinzerling, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4359 · Cited by 49 · see citing works
Myosite orbitaire associée à un traitement par ipilimumab
Lecouflet, M., Verschoore, M., Giard, C., Gohier, P., Corre, Y. L., Miléa, D., & Martin, L. (2013) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2013.02.029 · Cited by 48 · see citing works
Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma
du Rusquec, P., Saint-Jean, M., Brocard, A., et al. (2014) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000041 · Cited by 45 · see citing works
Abdallah, A.-O. A., Herlopian, A., Ravilla, R., Bansal, M., Chandra-Reddy, S., Mahmoud, F. A., Ong, S., Gökden, M., & Hutchins, L. F. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215572932 · Cited by 43 · see citing works
New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
Miserocchi, E., Cimminiello, C., Mazzola, M., Russo, V. E. A., & Modorati, G. M. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.10.010 · Cited by 35 · see citing works
Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review
Kopecký, J., Trojanova, P., ek, O. K., & Kopecký, O. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu222 · Cited by 33 · see citing works
Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report
Woźniak, S., Mackiewicz-Wysocka, M., Krokowicz, Ł., et al. (2015) · Oncology Research and Treatment · doi:10.1159/000377650 · Cited by 29 · see citing works
Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C
Sharma, A., Thompson, J. A., Repaka, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1946 · Cited by 26 · see citing works
Ipilimumab-Induced Hepatitis C Viral Suppression
Minter, S., Willner, I. R., & Shirai, K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5831 · Cited by 22 · see citing works
Wei, G., Nwakuche, U., Cadavid, G., et al. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-3 · Cited by 20 · see citing works
Solomon, L. R. (2015) · Acta Oncologica · doi:10.3109/0284186x.2014.1002572 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [63]63. Lecouflet M, Verschoore M, Giard C et al. [Orbital myositis associated with ipilimumab]. Ann Dermatol Venereol 2013; 140(6-7): 448-451.
- [70]70. Kyi C, Carvajal RD, Wolchok JD, Postow MA. Ipilimumab in patients with melanoma and autoimmune disease. J Immunother Cancer 2014; 2(1): 35.
Cited by
Sorted by citations
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713 · see citing works
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367 · see citing works
Self-citationToi, Y., Sugawara, S., Sugisaka, J., Ono, H., Kawashima, Y., Aiba, T., Kawana, S., Saito, R., Aso, M., Tsurumi, K., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5860 · Cited by 352 · see citing works
Santini, F. C., Rizvi, H., Plodkowski, A. J., Ni, A., Lacouture, M. E., Gambarin-Gelwan, M., Wilkins, O., Panora, E., Halpenny, D. F., Long, N. M., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0755 · Cited by 331 · see citing works
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P. (2019) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155217745144 · Cited by 331 · see citing works
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., Chan, D., Dusza, S., Motzer, R. J., Rosenberg, J. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02141 · Cited by 241 · see citing works
Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies
Chen, J. H., Pezhouh, M. K., Lauwers, G. Y., & Masia, R. (2017) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000829 · Cited by 186 · see citing works
Hayase, E., & Jenq, R. R. (2021) · Genome Medicine · doi:10.1186/s13073-021-00923-w · Cited by 145 · see citing works
PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer
Stenehjem, D., Tran, D., Nkrumah, M., & Gupta, S. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s135157 · Cited by 144 · see citing works
French Endocrine Society guidance on endocrine side effects of immunotherapy
Castinetti, F., Albarel, F., Archambeaud, F., Bertherat, J., Bouillet, B., Buffier, P., Briet, C., Cariou, B., Caron, P., Chabre, O., et al. (2019) · Endocrine Related Cancer · doi:10.1530/erc-18-0320 · Cited by 140 · see citing works
Self-citationAutoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107 · see citing works
Horisberger, A., La Rosa, S., Zurcher, J.-P., Zimmermann, S., Spertini, F., Coukos, G., & Obeid, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0481-0 · Cited by 81 · see citing works
Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies.
Bernard-Tessier, A., Jeanville, P., Champiat, S., Lazarovici, J., Voisin, A.-L., Mateus, C., Lambotte, O., Annereau, M., & Michot, J.-M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.017 · Cited by 78 · see citing works
Self-citationScanvion, Q., Béné, J., Gautier, S., Grandvuillemin, A., Le Beller, C., Chenaf, C., Etienne, N., Brousseau, S., Cortot, A. B., Mortier, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722022 · Cited by 59 · see citing works
“These drugs have been approved for the treatment of several cancers, including melanoma, non-small-cell lung cancer, urothelial carcinoma, renal cell carcinoma, squamous cell carcinoma of the head and the neck, and/or Hodgkin’s lymphoma.(2) However, ICIs are also associated with frequent and potentially organ- or life…”
Background
- Authors
- Champiat, S., Lambotte, O., Barreau, E., Belkhir, R., Berdelou, A., Carbonnel, F., Cauquil, C., Chanson, P., Collins, M., Durrbach, A., Ederhy, S., Feuillet, S., François, H., Lazarovici, J., Le Pavec, J., De Martin, E., Mateus, C., Michot, J.-M., Samuel, D., Soria, J.-C., Robert, C., Eggermont, A., & Marabelle, A.
- Affiliations
- Inserm (FR)
- Université Paris-Sud (FR)
- Bicêtre Hospital (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Corresponding author
- Marabelle, A.
- ORCID
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 27
- Issue
- 4
- Pages
- 559-574
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2289841322
- Semantic Scholar
- 6f7fdc9c00acb9d364605062654a4ee65c9212d8
- Cited by
- 903
- References
- 83
- Citations by year
- 2026: 25 · 2025: 45 · 2024: 60 · 2023: 61 · 2022: 86 · 2021: 122 · 2020: 123 · 2019: 121 · 2018: 115 · 2017: 107 · 2016: 37
- FWCI
- 37.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- immune checkpoint blockade, immune-related adverse events, immune dysregulation, CTLA-4 inhibitors, PD-1 inhibitors, immune checkpoint inhibitors, metastatic melanoma, non-small cell lung cancer
- MeSH terms
- Antibodies, Monoclonal, Carcinoma, Non-Small-Cell Lung, Humans, Immunotherapy, Melanoma, Disease Management, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
